Skip to content
  • Sunday, 26 July 2026
  • 4:30 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Japan’s Pharmaceutical Market Embraces Speed and Execution Amidst Global Pressures
Pharmaceutical R&D

Japan’s Pharmaceutical Market Embraces Speed and Execution Amidst Global Pressures

Teuku Ryan May 28, 2026 0

Japan’s pharmaceutical industry, the world’s third-largest by market value, is undergoing a significant and visible transformation. Historically characterized by methodical…

Read More
Pharmaceutical R&D

Paradigm Health Unveils AI-Powered Platform Revolutionizing Clinical Trial Execution

Teuku Ryan Apr 16, 2026 0

Paradigm Health is redefining the landscape of clinical research with its innovative, AI-powered platform designed to streamline the entire trial…

Read More
Biopharmaceutical Executives Express Record Optimism as Industry Navigates Disruption Through Strategic DealmakingThe Evolution of Creatine from Sports Supplement to Potential Therapeutic Agent for Cognitive and Systemic HealthStudy: Toxic Exposure in Pregnancy May Drive Disease Risk Across GenerationsTWiV 1285: Encapsidating Viruses 2025
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ